Abnova (Taiwan) Corporation (4133.TW)

TWD 27.9

(-0.36%)

Market Cap (In TWD)

1.68 Billion

Revenue (In TWD)

382.05 Million

Net Income (In TWD)

43.67 Million

Avg. Volume

172.05 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
27.7-38.0
PE
-
EPS
-
Beta Value
0.373
ISIN
TW0004133004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Yi Huang Huang
Employee Count
-
Website
https://www.abnova.com
Ipo Date
2009-12-28
Details
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.